A uniquely distributed purpuric drug eruption from acalabrutinib. (24th January 2022)

• Record Type: Journal Article
• Authors: Truong, Kelvin; Bhattacharyya, Abir; Kim, Jennifer; Wells, Jillian
• Is Part Of: Australasian journal of dermatology. Volume 63:Number 2(2022)
• Page Start: e142
• Page End: e144
• Publication Date: 2022-01-24
• Subjects: Acalabrutinib -- Bruton's tyrosine kinase inhibitor -- EGFR inhibitor -- Purpuric drug eruption -- Small vessel vasculitis; Dermatology -- Periodicals; Dermatology -- Australasia -- Periodicals; 616.5005
• DOI: 10.1111/ajd.13787
• Languages: English
• ISSNs: 0004-8380

Abstract

Abstract: Acalabrutinib is a second‐generation, highly selective Bruton's Tyrosine Kinase inhibitor (BTKi) indicated for use in some mature B‐cell malignancies. The authors describe a uniquely distributed drug reaction presenting as palpable purpura over the bilateral upper limbs. BTKi is theorised to cause haemorrhage through off‐target inhibition of Tec kinases and EGFR receptors. Dermatologists play an integral role in the multidisciplinary management of these patients to limit the negative impact on patient quality of life and, more importantly, to restrict dose reduction or treatment discontinuation.